AREC Stock Overview
A biopharmaceutical company, focuses on developing products in diabetes and other indications.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Arecor Therapeutics plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£1.31 |
52 Week High | UK£2.60 |
52 Week Low | UK£1.24 |
Beta | -0.21 |
1 Month Change | 1.95% |
3 Month Change | -15.48% |
1 Year Change | -48.63% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -45.87% |
Recent News & Updates
Shareholder Returns
AREC | GB Biotechs | GB Market | |
---|---|---|---|
7D | -4.0% | -0.1% | 0.1% |
1Y | -48.6% | -21.6% | 6.4% |
Return vs Industry: AREC underperformed the UK Biotechs industry which returned -19.3% over the past year.
Return vs Market: AREC underperformed the UK Market which returned 6.7% over the past year.
Price Volatility
AREC volatility | |
---|---|
AREC Average Weekly Movement | 4.3% |
Biotechs Industry Average Movement | 7.9% |
Market Average Movement | 4.9% |
10% most volatile stocks in GB Market | 11.2% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: AREC has not had significant price volatility in the past 3 months.
Volatility Over Time: AREC's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 51 | Sarah Howell | arecor.com |
Arecor Therapeutics plc, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo, a ready-to-use glucagon auto-injector pen that is used to treat hypoglycaemia in patients with diabetes; and specialty hospital care products.
Arecor Therapeutics plc Fundamentals Summary
AREC fundamental statistics | |
---|---|
Market cap | UK£40.12m |
Earnings (TTM) | -UK£8.55m |
Revenue (TTM) | UK£4.57m |
8.8x
P/S Ratio-4.7x
P/E RatioIs AREC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AREC income statement (TTM) | |
---|---|
Revenue | UK£4.57m |
Cost of Revenue | UK£0 |
Gross Profit | UK£4.57m |
Other Expenses | UK£13.13m |
Earnings | -UK£8.55m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.28 |
Gross Margin | 100.00% |
Net Profit Margin | -187.05% |
Debt/Equity Ratio | 0% |
How did AREC perform over the long term?
See historical performance and comparison